Reprint

Marine Compounds and Cancer 2020

Edited by
June 2021
480 pages
  • ISBN978-3-0365-0630-2 (Hardback)
  • ISBN978-3-0365-0631-9 (PDF)

This is a Reprint of the Special Issue Marine Compounds and Cancer that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary
The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.

Related Books

August 2021

Marine Natural Products as Anticancer Agents

Medicine & Pharmacology
June 2023

Marine Natural Products as Anticancer Agents 2.0

Medicine & Pharmacology
December 2015

Marine Compounds and Cancer

Medicine & Pharmacology
May 2018

Marine Compounds and Cancer 2017

Biology & Life Sciences